Glow LifeTech Corp.

Recent News

  • Glow LifeTech Reports Positive Preliminary Results from Clinical Study of Artemic Support(R) on Patients with Long COVID Syndrome

    Clinical Study results indicate the potential ability of Glow Lifetech's ArtemiC Support® to reduce symptoms of Post-Acute COVID Syndrome (Long COVID).Study results demonstrate the statistically significant reduction in severity of a range of Long COVID symptoms, including Dyspnea (shortness of breath), Cough, Asthenia (physical weakness/lack of energy), Headache and Mental Confusion.150 Patients were administered ArtemiC Support® during a 6-week period under the supervision of their doctor, with their progress measured against a Post-COVID Functional Scale (PCFS), and symptoms on a...

    2022-07-18 8:46 PM EDT
  • Glow Announces Extension of Warrant Expiry

    Toronto, Ontario--(Newsfile Corp. - July 14, 2022) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), is pleased to announce that it has extended the expiry date of an aggregate of 8,569,217 previously issued warrants (the "Warrants"). The Warrants were originally issued by the Company on March 3, 2021 at an exercise price of $0.40 per common share. The Warrants have been extended for an additional two (2) years, with the amended expiry being March...

    2022-07-14 4:05 PM EDT
  • Glow Provides Update on Cannabis Development Activities and Ongoing Clinical Studies

    Toronto, Ontario--(Newsfile Corp. - July 7, 2022) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), is pleased to provide an update on commercial operations, cannabis-related development activities and clinical studies related to its proprietary MyCell®-enhanced products. Glow is now focused on the final stages of development of proprietary CBD (cannabidiol) and THC1 (tetrahydrocannabinol) water-soluble ingredients in preparation for launch in Canada. With Glow's licensed cannabis processing space now built out and equipment successfully commissioned earlier...

    2022-07-07 4:00 PM EDT
  • Glow Completes Reactor Commissioning and Initiates Development of Proprietary MyCell(R) Water-Soluble Cannabis Ingredients

    Toronto, Ontario--(Newsfile Corp. - January 11, 2022) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to announce it has completed the commissioning of its reactor production equipment and initiated development of its high-performance, water-soluble MyCell® cannabis ingredients at its Canadian processing facility. MyCell® technology also powers Artemic Support®, which is currently involved in a Long-Covid clinical study that is expected to be completed by...

    2022-01-11 3:00 AM EST
  • Glow Appoints Scientific & Regulatory Expert Advisors to Advance Commercial Activities

    Toronto, Ontario--(Newsfile Corp. - December 29, 2021) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to welcome scientific and regulatory experts Scott Sawler, Dr. Murray Berall and Dr. Melissa Lewis-Bakker and as the initial appointees to the Company's Technical Advisory Board. The three advisors will provide counsel and guidance on the technical, regulatory and clinical aspects of Glow's product lines of advanced nutraceutical and...

    2021-12-29 4:00 PM EST
  • Glow LifeTech Announces Commencement of Clinical Study of Artemic Support Featuring MyCell Technology on Patients with Long COVID

    Toronto, Ontario--(Newsfile Corp. - December 24, 2021) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to announce that it is co-sponsoring a clinical study (the "Study") to assess the impact of its proprietary natural health product Artemic Support®, which features MyCell® Technology, in patients with Long COVID syndrome.Post-acute COVID syndrome (PACS) or "Long COVID" presents itself as a wide range of ongoing symptoms...

    2021-12-24 1:00 PM EST
  • Glow Completes Buildout of Canadian Facility and Begins Commissioning Proprietary Reactor

    Toronto, Ontario--(Newsfile Corp. - November 9, 2021) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to announce it has completed the buildout of its licensed processing space ("Processing Space") in Canada and has begun commissioning its reactor production equipment which enables the production of its high-performance MyCell® ingredients. Glow has completed the buildout of its first production facility, located in Toronto, Canada, which will...

    2021-11-09 3:00 AM EST
  • Glow LifeTech Reports Positive Preclinical Data on Proprietary MyCell CBD Demonstrating Superior Bioavailability and Rapid Onset Time

    Toronto, Ontario--(Newsfile Corp. - November 4, 2021) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), a biotech company focused on producing next-generation, science-backed natural ingredients, is pleased to report positive results from a preclinical pharmacokinetic study evaluating its advanced MyCell® CBD concentrate against traditional CBD oil. Overall, MyCell® CBD formulation demonstrated fast-acting absorption in under 15 minutes and 13x greater absorption of CBD at 60 minutes, providing scientific evidence of MyCell® Technology's industry...

    2021-11-04 5:00 PM EDT